NOW RECRUITING: Iovance is conducting a Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145-03) followed by IL-2 in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Key eligibility criteria:
• Measurable metastatic disease and ≥ 1 lesion resectable for TIL generation
• At least one prior systemic therapy
• Age ≥ 18
• ECOG PS 0-1
Endpoints: Safety and Efficacy